Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 20/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 1.00 |
| ▸ | KDM5C | P41229 | 1/20 | 1.00 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 1.00 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 1.00 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31236648 | 0.99 | KDM5A (0.98) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL29678217 | 0.79 | KDM5A (1.00) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2125534 | 0.71 | KDM5A (0.61) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2123873 | 0.69 | KDM5A (0.58) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL29549639 | 0.69 | KDM5A (1.00) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2873336 | 0.68 | KDM5A (0.55) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2124968 | 0.68 | KDM5A (0.64) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2124746 | 0.68 | KDM5A (0.52) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2126197 | 0.67 | KDM5A (0.53) | KDM5AKDM6BKDM5CKDM5DKDM4C | |
| SCHEMBL2125864 | 0.66 | KDM5A (0.62) | KDM5AKDM6BKDM5CKDM5DKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137885-A | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-06-13 | — | — | CN | claimed |
| CN-119792523-A | Application of KDM5B inhibitor in preparation of medicine for treating EBV-related epithelial tumors | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 2025-04-11 | — | — | CN | claimed |
| WO-2025059442-A1 | MODULATING PLANT RESPONSES TO STRESS AND GROWTH WITH CHEMICALS | REMOTE EPIGENETICS INC. (US) | 2025-03-20 | — | — | WO | claimed |
| EP-4072546-B1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIV ANTWERPEN (BE) | 2025-02-19 | — | — | EP | claimed |
| WO-2024233765-A1 | THERAPEUTIC APPROACH TO BLOCK TERMINAL EXHAUSTION OF T CELLS AND SYNERGIZE THE EFFICACY OF T CELL IMMUNOTHERAPIES | OHIO STATE INNOVATION FOUNDATION (US) | 2024-11-14 | — | — | WO | claimed |
| WO-2024210580-A1 | COMPOSITION FOR INDUCING STEM CELLS TO DIFFERENTIATE INTO ASTROCYTES, CONTAINING CPI-455 | 중앙대학교 산학협력단 | 2024-10-10 | — | — | WO | claimed |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-05-02 | — | — | US | claimed |
| CN-117126802-A | Method for in vitro induction of directional differentiation of embryonic stem cells into myocardial cells | 广州医科大学附属第五医院(广州再生医学与健康广东省实验室附属医院) | 2023-11-28 | — | — | CN | claimed |
| US-20230038503-A1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | UNIVERSITEIT ANTWERPEN (BE) | 2023-02-09 | — | — | US | claimed |
| EP-4072546-A1 | INHIBITORS OF KDM5A FOR USE IN TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES | Universiteit Antwerpen (BE) | 2022-10-19 | — | — | EP | claimed |
| EP-4058604-B1 | COMPOSITIONS AND METHODS FOR REGULATING EGFR AMPLIFICATION IN CANCER CELLS FOR IMPROVING EGFR-TARGETED ANTI-CANCER AGENT | INSTITUTE FOR CANCER RES (US) | 2026-04-22 | — | — | EP | disclosed |
| JP-2026511977-A | — | チュンアン・ユニヴァーシティ・インダストリー・アカデミック・コーペレーション・ファウンデーション | 2026-04-14 | — | — | JP | disclosed |
| JP-2026511977-A | — | チュンアン・ユニヴァーシティ・インダストリー・アカデミック・コーペレーション・ファウンデーション | 2026-04-14 | — | — | JP | disclosed |
| US-12589160-B2 | Peptide-derived therapeutics targeting KDM5C for the treatment of cancer | NUVOBIO CORPORATION (CA) | 2026-03-31 | — | — | US | disclosed |
| CN-120137885-B | Culture solution additive for improving embryo development potential and application thereof | 山东大学 | 2025-12-02 | — | — | CN | disclosed |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | UNITED STATES GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | Frequency Therapeutics, Inc. (US) | 2022-04-28 | — | — | US | disclosed |
| CN-114340611-A | Combination of CHIR99021 and valproic acid for the treatment of hearing loss | 频率医疗公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3952854-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | Frequency Therapeutics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127568-A1 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS | WNT3A, WNT1, MECP2 | KDM5A 291/4885KDM6B 102/4885KDM5C 243/4885 |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | KDM5A, KDM5B, KDM5C | KDM5A 1/4885KDM6B 14/4885KDM5C 3/4885 |
| US-20220175776-A1 | COMBINATION OF CHIR99021 AND VALPROIC ACID FOR TREATING HEARING LOSS | HES1, SHH, HDAC11 | KDM5A 760/4885KDM6B 459/4885KDM5C 1389/4885 |
| US-12589160-B2 | Peptide-derived therapeutics targeting KDM5C for the treatment of cancer | SUV39H1, SUV39H2, SMYD2 | KDM5A 17/4885KDM6B 36/4885KDM5C 19/4885 |
| US-20220160664-A1 | TAZ ACTIVATORS AND WNT AGONISTS FOR TREATING EAR DISORDERS | WNT1, WNT3A, CTNNB1 | KDM5A 4354/4885KDM6B 4103/4885KDM5C 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.